Drug Profile

Research programme: anti-Alzheimer's therapeutics transdermal - ALZYN

Latest Information Update: 28 Oct 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Oct 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Transdermal, Spray)
20 Sep 2016 ALZYN and Transdermal Delivery Solutions enter into an agreement for licensing of a transdermal HypoSpray^®-delivered solution
20 Sep 2016 ALZYN in-licenses science from Florida State Research Foundation for development of transdermally administered therapeutics for Alzheimer's disease

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com